In our study, we demonstrated that SF-PreCon exerts cardioprotective effect by significantly increasing pERK1/2 levels in DM and AMPK-DN mice (underlining its AMPK-independent mechanism), while suppressing ERK1/2 activity in WT mice. The gene discussed is PRKAA2; the disease is diabetes mellitus.